Illumina sees 2025 EPS of $4.50
Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...
Illumina said at the time that it was working to find a solution. “We respect and abide by Chinese laws and regulations,” the ...
At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.
Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...
Illumina is a prominent entity in the genomic sequencing market, providing advanced DNA sequencing platforms and associated products. Its technologies are vital across research, clinical ...
Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...
To help researchers work towards these goals, Illumina has devised two methods for sequencing SARS-CoV-2 from clinical samples: one workflow based on shotgun metagenomics, and one on target ...
Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback